Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 As an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults with Bacteremia Due to Staphylococcus Aureus

Next Previous
Search
Trial Profile

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 As an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults with Bacteremia Due to Staphylococcus Aureus

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP-SA02 (Primary) ; Antibacterials
  • Indications Bacteraemia; Staphylococcal infections
  • Focus Adverse reactions; First in man
  • Acronyms diSArm Study
  • Sponsors Armata Pharmaceuticals

Most Recent Events

  • 01 May 2025 According to an Armata Pharmaceuticals media release, topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial
  • 01 May 2025 According to an Armata Pharmaceuticals media release, company Received 4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support diSArm Clinical Trial of AP-SA02. The amount will be used to support Phase 2a study close out activities as well as for the preparation and execution of an end-of-phase 2 meeting with the U.S. Food and Drug Administration.
  • 26 Mar 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top